MDL 3026 Bellwether: Inman v. Mead Johnson Goes to Trial
The first federal bellwether trial in MDL 3026, In re Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation, opened July 6, 2026 in the Northern District of Illinois before Judge Rebecca Pallmeyer. Plaintiff Alexis Inman alleges that Enfamil cow's-milk formula caused the necrotizing enterocolitis death of infant Daniel Inman. With 810 MDL cases pending, the verdict, still outstanding at press time, will anchor settlement trajectory across the consolidated docket.
The trial's significance stems from what it survived. Judge Pallmeyer denied Mead Johnson's summary judgment motion on May 8, 2026, and separately preserved the causation testimony of epidemiologist Dr. Logan Spector, making this the first Enfamil case to clear federal summary judgment. Mead Johnson won a state-court defense verdict reported July 2, 2026, just days before the federal trial opened, confirming that causation science on NEC remains genuinely contested across venues.
State-court verdicts frame the stakes. An April 2026 Chicago jury awarded $70M to four families over Abbott's Similac premature formula in Cook County state court, building on a $495M Missouri jury verdict from July 2024 and a $60M Illinois state verdict from March 2024. Counsel on both sides will read the Inman outcome as a signal on whether federal causation standards compress or expand that state-court range.
Bar takeaway: A plaintiff verdict in Inman accelerates global settlement pressure on all 810 MDL plaintiffs; a defense verdict narrows Dr. Spector's cross-venue utility without foreclosing state-court routing.
North Carolina's Largest Brachial Plexus Verdict: Maxwell Lake v. WakeMed
A Wake County Superior Court jury returned an $18.2M verdict on July 14, 2026 in Naqah Maxwell Lake v. WakeMed (File No. 22CVS011664-910), awarding $2.2M in economic damages and $16M in noneconomic damages. Brachial plexus palsy was caused during delivery on September 17, 2019, when a resident physician performed a fetal vertex rotation during shoulder dystocia, a technique that Grant & Eisenhofer trial partners Lisa Weinstein and Gerald Jowers described at trial as a 'never maneuver.'
The verdict is reported as North Carolina's largest brachial plexus birth-injury award. One procedural caveat controls the payment timeline: North Carolina General Statute section 90-21.19 caps noneconomic damages in medical malpractice actions and requires judicial review before any payment on the $16M noneconomic component. Whether the cap reduces that figure is the central post-verdict question.
Bar takeaway: Counsel with pending NC birth-injury matters should immediately audit exposure under section 90-21.19 and document the economic-loss breakdown before the statutory cap review hearing.
Talc Appeal: Garcia v. J&J Survives Illinois Appellate Review
On July 10, 2026, the Illinois First District Appellate Court affirmed a $45M talc and mesothelioma verdict against Johnson & Johnson and Kenvue. The damages award includes a $30M 'reduced lifespan' component, quantifying the statistical difference between the plaintiff's expected longevity and actual post-diagnosis trajectory. Plaintiffs' counsel in standard product-liability and med-mal cases have begun importing this noneconomic theory into their damages frameworks outside the mass-tort context.
Johnson & Johnson is seeking Illinois Supreme Court review. The affirmance matters well beyond the talc MDL because it signals that Illinois appellate courts will sustain large noneconomic components tied to statistical life-expectancy reduction, a theory that maps onto surgical-injury cases, delayed-cancer-diagnosis cases, and any matter where a plaintiff can quantify the actuarial difference between expected longevity and post-injury trajectory. Firms litigating those case types in Illinois should track the cert petition filing date.
Bar takeaway: The $30M 'reduced lifespan' component in Garcia now has an Illinois appellate imprimatur; apply the theory in any case where defendant conduct shortened a measurable life expectancy.
Seven Consecutive Premium Years: Nuclear Verdicts and the Insurance Market
Medical malpractice premiums are rising for the seventh consecutive year, reaching rate-increase territory not seen since the early 2000s. Nuclear verdicts (those exceeding $10M) increased 52% from 2023 to 2024, and the top 50 U.S. verdicts averaged $56M. Pennsylvania and New York experienced the steepest carrier-side increases, with social inflation, third-party litigation funding, and nuclear-verdict frequency identified as primary drivers.
For PI firms running medical-provider relationships on a lien basis, this environment carries direct operational implications. As premiums compress provider margins, hospitals and surgery centers face increased pressure to resolve liens quickly and clear accounts receivable. Providers working with PI firms through lien arrangements, including those listed on structured lien directories, gain a quantifiable cash-flow argument when negotiating resolution timelines: faster lien turnover directly offsets rising insurance overhead.
The 52% nuclear verdict increase also affects coverage limits offered to defendants, putting a practical ceiling on settlement where primary coverage is exhausted. Auditing defendant insurance limits and excess-layer availability early in case evaluation is now a material step, not administrative routine.
Bar takeaway: Request defendant coverage disclosures and excess-layer confirmation at the outset; coverage compression in a rising-premium market is now a material settlement variable.
Telehealth Liability and FDA Device Recalls: Expanding Exposure
Courts in 2026 apply the same standard-of-care framework to telehealth encounters as to in-person visits. The Centers for Medicare and Medicaid Services and the Office of Inspector General intensified Medicare telehealth billing scrutiny this year, creating a parallel compliance-and-liability risk track for remote providers. The primary liability exposure is using telehealth for conditions that require hands-on examination, urgent diagnostic testing, or immediate procedural intervention. A provider who diagnoses via video a patient who later presents with a missed acute condition faces the same malpractice exposure as if the encounter had been in-person. Cross-state telehealth adds further risk: malpractice coverage may not extend across state lines without an explicit policy endorsement, leaving coverage gaps for both the treating provider and any referring practice.
Two FDA Class I recalls carry active PI exposure as of this week. The Abiomed/Oscor catheter introducer (recall notice June 22, 2026) presents bleeding-risk defects in catheter-introduction devices. Zoll ventilators, AEDs, and electrodes were separately cited at Class I severity, meaning FDA found a reasonable probability of serious injury or death. A GAO report (GAO-26-107619) identified process limitations in FDA's recall-oversight function, a finding useful to plaintiffs arguing that the recall system fails to provide adequate notice to end users and clinical staff.
Bar takeaway: In any case involving a recalled Abiomed or Zoll device, obtain the FDA 510(k) clearance history, the Class I recall notice, and GAO-26-107619 to support a failure-to-warn or post-sale duty-to-recall argument.
Post-Durnell Playbook and California Lien Operations
The Supreme Court's 7-2 decision in Monsanto Co. v. Durnell (No. 24-1068, June 25, 2026) held that FIFRA preempts state failure-to-warn claims on EPA-approved pesticide labels, collapsing the dominant liability theory across roughly 160,000 pending Roundup and glyphosate suits. The plaintiff mass-tort bar is building a replacement framework around design-defect, manufacturing-defect, and advertising claims that avoid the preempted label-warning theory.
On the lien management side, California practice reflects growing complexity in proportional Medicare procurement-cost reductions and ERISA self-funded plan negotiability. The 2025 decision in Prahl v. Allstate Northbrook, 110 Cal.App.5th 118, continues to circulate as a cautionary illustration on UIM arbitration deadline management for firms whose medical-lien resolution timelines track arbitration scheduling. Providers evaluating lien-based referral relationships should understand that ERISA self-funded plan liens present negotiability parameters distinct from Medicare and Medicaid subrogation claims, a distinction that affects net-recovery calculations determining whether plaintiffs can sustain liens through resolution.
Bar takeaway: Whether the Illinois Supreme Court accepts Garcia for review is the next date to calendar for firms applying the 'reduced lifespan' noneconomic theory statewide.